-$0.61 EPS Expected for uniQure (NASDAQ:QURE) This Quarter

Equities analysts expect uniQure (NASDAQ:QURE – Get Rating) to post earnings of ($0.61) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for uniQure’s earnings, with estimates ranging from ($1.20) to $1.16. uniQure posted earnings of ($0.91) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 33%. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that uniQure will report full-year earnings of ($2.66) per share for the current fiscal year, with EPS estimates ranging from ($4.30) to ($0.21). For the next year, analysts anticipate that the business will report earnings of ($2.30) per share, with EPS estimates ranging from ($3.85) to $0.42. Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for uniQure.

uniQure (NASDAQ:QURE – Get Rating) last announced its quarterly earnings results on Friday, February 25th. The biotechnology company reported $0.17 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.89. The business had revenue of $57.69 million for the quarter, compared to analyst estimates of $25.12 million. uniQure had a return on equity of 64.35% and a net margin of 62.90%.

Several research analysts recently weighed in on QURE shares. Zacks Investment Research lowered shares of uniQure from a “hold” rating to a “sell” rating in a research note on Thursday, March 3rd. Raymond James lowered shares of uniQure from a “strong-buy” rating to an “outperform” rating and cut their price objective for the stock from $75.00 to $58.00 in a research report on Thursday, December 16th. UBS Group raised shares of uniQure from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a research report on Thursday, March 17th. Chardan Capital lowered their price objective on uniQure from $95.00 to $65.00 in a research note on Wednesday, March 30th. Finally, StockNews.com assumed coverage on uniQure in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, uniQure currently has a consensus rating of “Buy” and an average target price of $52.06.

uniQure stock traded up $0.36 on Tuesday, reaching $18.81. The company’s stock had a trading volume of 15,146 shares, compared to its average volume of 473,702. The company has a debt-to-equity ratio of 0.17, a quick ratio of 17.09 and a current ratio of 17.09. uniQure has a twelve month low of $14.29 and a twelve month high of $38.80. The stock has a market capitalization of $873.91 million, a P/E ratio of 2.70 and a beta of 1.05. The company’s fifty day moving average is $17.10.

In related news, CFO Christian Klemt sold 4,075 shares of the company’s stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $16.80, for a total value of $68,460.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 10,195 shares of the firm’s stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $16.70, for a total value of $170,256.50. The disclosure for this sale can be found here. Insiders sold a total of 40,111 shares of company stock valued at $698,006 in the last 90 days. 2.66% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. Morgan Stanley grew its position in uniQure by 114.4% during the second quarter. Morgan Stanley now owns 105,734 shares of the biotechnology company’s stock valued at $3,256,000 after acquiring an additional 56,427 shares during the period. Hudson Bay Capital Management LP grew its stake in uniQure by 12.5% during the 3rd quarter. Hudson Bay Capital Management LP now owns 260,000 shares of the biotechnology company’s stock worth $8,323,000 after buying an additional 28,900 shares during the last quarter. American Century Companies Inc. bought a new stake in shares of uniQure during the third quarter valued at approximately $1,062,000. New York State Teachers Retirement System acquired a new stake in uniQure in the third quarter worth about $301,000. Finally, Handelsbanken Fonder AB raised its stake in shares of uniQure by 55.3% in the 3rd quarter. Handelsbanken Fonder AB now owns 11,800 shares of the biotechnology company’s stock worth $378,000 after buying an additional 4,200 shares in the last quarter. 81.40% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile (Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Recommended Stories